Cargando…

Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year

Recombinant tissue plasminogen activator (rt-PA) is used to restore patency and avoid inadvertent removal of peripheral and central venous catheters. rt-PA was reconstituted (1 mg/mL) then cryopreserved at −30 °C for 1, 2, 3, 6, 8, and 12 months and, then its stability was determined. After cryopres...

Descripción completa

Detalles Bibliográficos
Autor principal: Alkatheri, Abdulmalik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816680/
https://www.ncbi.nlm.nih.gov/pubmed/24275785
http://dx.doi.org/10.3390/ph6010025
_version_ 1782477971775291392
author Alkatheri, Abdulmalik
author_facet Alkatheri, Abdulmalik
author_sort Alkatheri, Abdulmalik
collection PubMed
description Recombinant tissue plasminogen activator (rt-PA) is used to restore patency and avoid inadvertent removal of peripheral and central venous catheters. rt-PA was reconstituted (1 mg/mL) then cryopreserved at −30 °C for 1, 2, 3, 6, 8, and 12 months and, then its stability was determined. After cryopreservation for one and two months, rt-PA kept more than 95% of its activity compared to standard samples, while cryopreservation for three months caused 8% loss of activity. However, after cryopreservation for six months or more, rt-PA retained only 87.5% or less activity compared to standard samples. Therefore, it is recommended that reconstituted rt-PA be cryopreserved at −30 °C for a maximum period of three months.
format Online
Article
Text
id pubmed-3816680
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38166802013-11-14 Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year Alkatheri, Abdulmalik Pharmaceuticals (Basel) Article Recombinant tissue plasminogen activator (rt-PA) is used to restore patency and avoid inadvertent removal of peripheral and central venous catheters. rt-PA was reconstituted (1 mg/mL) then cryopreserved at −30 °C for 1, 2, 3, 6, 8, and 12 months and, then its stability was determined. After cryopreservation for one and two months, rt-PA kept more than 95% of its activity compared to standard samples, while cryopreservation for three months caused 8% loss of activity. However, after cryopreservation for six months or more, rt-PA retained only 87.5% or less activity compared to standard samples. Therefore, it is recommended that reconstituted rt-PA be cryopreserved at −30 °C for a maximum period of three months. MDPI 2012-12-31 /pmc/articles/PMC3816680/ /pubmed/24275785 http://dx.doi.org/10.3390/ph6010025 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Alkatheri, Abdulmalik
Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year
title Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year
title_full Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year
title_fullStr Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year
title_full_unstemmed Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year
title_short Stability of Recombinant Tissue Plasminogen Activator at −30 °C Over One Year
title_sort stability of recombinant tissue plasminogen activator at −30 °c over one year
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816680/
https://www.ncbi.nlm.nih.gov/pubmed/24275785
http://dx.doi.org/10.3390/ph6010025
work_keys_str_mv AT alkatheriabdulmalik stabilityofrecombinanttissueplasminogenactivatorat30coveroneyear